Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 - - Oncology pipeline advancing with novel LockBody technology - - Announces discontinuation of ZF874
10.08.2022 - - Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected .
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs
Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs - read this article along with other careers information, tips and advice on BioSpace